Sean Ainsworth hopes to strike biotech gold, again, joining Seattle-based Immusoft Corp. as CEO and chairman. Immusoft is a gene-therapy company that hopes to use a patient’s immune cells to treat diseases, including MPS-I, or mucopolysaccharidosis type I, a rare genetic disease that is expected to be Immusoft’s first clinical application. The company uses a cell-culture system invented by Nobel laureate David Baltimore that it calls Immune System Programming.
Immusoft is looking to get its gene therapy technology into clinical trials, and the Seattle startup announced Friday that it has raised $3 million to kickstart that process. The funding is first part of the company’s ongoing Series B…. Veteran biotech executive Sean Ainsworth is joining the company as its new CEO, filling the shoes of the company’s Founder and longtime CEO Matthew Scholz. Scholz is transitioning to become the company’s CTO and will retain his position on the board of directors.
SEATTLE, Wash. (November 1, 2016)— Immusoft Corporation, a Seattle, Wash.-based gene therapy company, has closed on $2.74 million of a $3 million fundraising round. Founders Fund’s FF Science and Technium Partners led the investment. The round was oversubscribed and Immusoft says it expects to close on the remaining amount shortly.
